Macrolide Use in the Treatment of Critically Ill Patients with Pneumonia: Incidence, Correlates, Timing and Outcomes | Zendy

Wendy Sligl | Zendy; Holly Hoang | Zendy; Dean T. Eurich | Zendy; Atul Malhotra | Zendy; Thomas J. Marrie | Zendy; Sumit R. Majumdar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Macrolide Use in the Treatment of Critically Ill Patients with Pneumonia: Incidence, Correlates, Timing and Outcomes

Author(s) -

Wendy Sligl,

Holly Hoang,

Dean T. Eurich,

Atul Malhotra,

Thomas J. Marrie,

Sumit R. Majumdar

Publication year - 2013

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.634

H-Index - 38

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2013/652512

Subject(s) - medicine , pneumonia , pneumonia severity index , incidence (geometry) , apache ii , cohort , population , antibiotics , cohort study , intensive care medicine , community acquired pneumonia , intensive care unit , physics , optics , microbiology and biotechnology , environmental health , biology

Macrolide antibiotics are commonly used to treat pneumonia despite increasing antimicrobial resistance. Evidence suggests that macrolides may also decrease mortality in severe sepsis via immunomodulatory properties.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research